Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IMVT vs XNCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMVT Captures Overall Composite Edge (39.6 SELL vs 29.6 SELL), While XNCR Leads 4–2 on Growth & Valuation Pillars

IMVT Overall Winner 6-Pillar Tally: IMVT 2 – 4 XNCR Matrix Metrics: IMVT 5 – 5 XNCR

As of Nov 16, 2026, Immunovant, Inc. (IMVT) captures the overall head-to-head institutional edge over Xencor, Inc. (XNCR) on higher Unified Composite conviction (39.6/100 SELL vs. 29.6/100 SELL) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while XNCR wins 4–2 across the 6-pillar growth and valuation breakdown. IMVT trades at $33.30 (N/M Forward P/E, 0.0% operating margin) versus XNCR at $35.61 (68.0x Forward P/E, -72.7% operating margin).

  • Growth vs. Quality Trade-Off: IMVT earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. XNCR 29.6/100 SELL) and 1.74β · 72% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both IMVT (39.6/100 SELL) and XNCR (29.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMVT vs XNCR
IMVT NASDAQ Head-to-Head Winner
Immunovant, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$33.30
-2.56% 1D
Market Cap $7.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 72% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 36.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $30.82 · SMA50: $32.52
XNCR NASDAQ
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52

6-Pillar Scorecard Institutional Category Breakdown (IMVT 2 – 4 XNCR)

Columns: Metric · IMVT · XNCR
1. Valuation Multiples XNCR
Forward P/E N/M 68.0x
Trailing P/E N/M 68.0x
PEG Ratio N/M N/M
EV / Revenue N/M 14.8x
2. Growth & Scale XNCR
Revenue Growth (YoY) +0.0% +454.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $200M
Market Cap $7.3B $2.9B
3. Profitability & Quality IMVT
Gross Margin N/A -42.5%
Operating Margin 0.0% -72.7%
Net Profit Margin 0.0% -58.8%
Return on Equity (ROE) -86.5% -19.9%
4. Balance Sheet & Cash Flow XNCR
Cash Generation (TTM) -$395M -$176M
Cash Flow Margin N/A -88.0%
Net Cash / Leverage $3.18 Book/Sh · -86.5% ROE $101M Net Debt (0.29x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMVT
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 54.1% (6th %ile) 79.0% (10th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity N/A 30.2% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMVT (5) vs XNCR (5)
Institutional Metric IMVT XNCR Criterion Row Edge
Market Capitalization
Scale
$7.3B $2.9B Larger Scale IMVT
Trailing P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Forward P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Revenue Growth (YoY)
Growth
+0.0% +454.9% Higher Growth XNCR
Operating Margin (TTM)
Profitability
0.0% -72.7% Higher Margin IMVT
Net Profit Margin
Profitability
0.0% -58.8% Higher Margin IMVT
Return on Equity (ROE)
Capital Efficiency
-86.5% -19.9% Higher ROE XNCR
52-Week Range Position
Momentum
49% ($22–$45) 84% ($10–$41) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.74β · 72% Vol 1.21β · 87% Vol Lower Realized Risk IMVT
Unified Institutional Score
Composite Signal
39.6 / 100 (SELL) 29.6 / 100 (SELL) Higher Composite IMVT
Trailing 12M Revenue (USD)
Operating Scale
N/A $200M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -42.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$395M ($3.18 Book/Sh · -86.5% ROE) -$176M ($101M Net Debt (0.29x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +31.24 pp
IMVT: +24.6% · XNCR: +55.84%
3M Horizon XNCR +64.96 pp
IMVT: -24.82% · XNCR: +40.14%
6M Horizon XNCR +196.43 pp
IMVT: +25.54% · XNCR: +221.97%
1Y Horizon XNCR +108.59 pp
IMVT: +45.95% · XNCR: +154.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMVT vs XNCR. Trailing 12-month operating profitability (IMVT 0.0% vs XNCR -72.7%) and valuation multiples (IMVT N/M vs XNCR 68.0x Forward P/E) are benchmarked directly in Pillar 4 below.

IMVT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-86.5% · N/M
XNCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$200M
Gross Margin-42.5%
Op. Margin-72.7%
ROE / Fwd P/E-19.9% · 68.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMVT CONSOLIDATION
93d in phase · OBV ACCUMULATION
Current IV 54.1%
IV Percentile 6th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ IMVT vs XNCR Key Questions & Quantitative Answers

As of Nov 16, 2026, Immunovant, Inc. (IMVT) captures the overall head-to-head institutional edge over Xencor, Inc. (XNCR) on higher Unified Composite conviction (39.6/100 SELL vs. 29.6/100 SELL) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while XNCR wins 4–2 across the 6-pillar growth and valuation breakdown. IMVT trades at $33.30 (N/M Forward P/E, 0.0% operating margin) versus XNCR at $35.61 (68.0x Forward P/E, -72.7% operating margin). Growth vs. Quality Trade-Off: IMVT earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. XNCR 29.6/100 SELL) and 1.74β · 72% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both IMVT (39.6/100 SELL) and XNCR (29.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

XNCR leads the Growth & Scale pillar: IMVT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with XNCR at +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin). On trailing 12-month operating scale, IMVT generates N/A in USD-normalized revenue versus $200M for XNCR. In operating R&D and SG&A reinvestment, IMVT deploys N/A (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($61M) (0 disclosures) for XNCR.

XNCR screens cheaper on headline valuation multiples. IMVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMVT (-86.5% ROE) versus XNCR (-19.9% ROE) capital efficiency.

In options market volatility and institutional positioning, IMVT carries 54.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 72% Vol realized risk). By comparison, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.